Ultimovacs ASA Total Assets
Ultimovacs ASA total assets. Based on the latest financial reports, Ultimovacs ASA (ULTI) holds total assets worth Nkr115.86 Million NOK (≈ $12.19 Million USD) as of December 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Ultimovacs ASA stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Ultimovacs ASA (2016–2024)
Total assets of Ultimovacs ASA from 2016 to 2024. This chart illustrates how Ultimovacs ASA's total assets have evolved over time, based on quarterly financial data. See latest Ultimovacs ASA stock price today for real-time trading data and today's change.
Ultimovacs ASA - Asset Composition Analysis
Ultimovacs ASA Total Assets Breakdown (December 2024)
Ultimovacs ASA total assets breakdown as of December 2024. Ultimovacs ASA's total assets of Nkr115.86 Million consist of 98.3% current assets and 1.7% non-current assets.
| Asset Category | Amount (NOK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Nkr0.00 | 92.7% |
| Accounts Receivable | Nkr0.00 | 0.0% |
| Inventory | Nkr0.00 | 0.0% |
| Property, Plant & Equipment | Nkr0.00 | 0.0% |
| Intangible Assets | Nkr0.00 | 0.0% |
| Goodwill | Nkr0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Ultimovacs ASA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ULTI working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ultimovacs ASA's current assets represent 98.3% of total assets in 2024, an increase from 94.6% in 2016.
- Cash Position: Cash and equivalents constituted 92.7% of total assets in 2024, up from 87.5% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 4.0% in 2016.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Ultimovacs ASA Competitors by Total Assets
Key competitors of Ultimovacs ASA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Ultimovacs ASA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.62 | 4.85 | 19.29 |
| Quick Ratio | 3.62 | 4.85 | 19.29 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Nkr82.36 Million | Nkr216.01 Million | Nkr357.77 Million |
Ultimovacs ASA - Advanced Valuation Insights
This section examines the relationship between Ultimovacs ASA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.52 |
| Latest Market Cap to Assets Ratio | 0.45 |
| Asset Growth Rate (YoY) | -66.8% |
| Total Assets | Nkr115.86 Million |
| Market Capitalization | $52.14 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ultimovacs ASA's assets below their book value (0.45x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Ultimovacs ASA's assets decreased by 66.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Ultimovacs ASA (2016–2024)
The table below shows the annual total assets of Ultimovacs ASA from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr115.86 Million ≈ $12.19 Million |
-66.81% |
| 2023-12-31 | Nkr349.04 Million ≈ $36.73 Million |
-31.52% |
| 2022-12-31 | Nkr509.67 Million ≈ $53.63 Million |
-22.25% |
| 2021-12-31 | Nkr655.54 Million ≈ $68.98 Million |
+23.75% |
| 2020-12-31 | Nkr529.72 Million ≈ $55.74 Million |
+10.81% |
| 2019-12-31 | Nkr478.04 Million ≈ $50.30 Million |
+151.79% |
| 2018-12-31 | Nkr189.86 Million ≈ $19.98 Million |
+6.17% |
| 2017-12-31 | Nkr178.82 Million ≈ $18.82 Million |
+116.42% |
| 2016-12-31 | Nkr82.63 Million ≈ $8.69 Million |
-- |
About Ultimovacs ASA
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.